Related Experiment Video
Updated: Jul 15, 2025
08:49
Murine Ileocolic Bowel Resection with Primary Anastomosis
Published on: October 29, 2014
16.5K
Are We Ready to Reclassify Crohn's Disease Using Molecular Classification?
Shahed Kamal1, Nikita Parkash2, William Beattie2
1Department of Gastroenterology, Northern Hospital, Epping, Melbourne VIC 3076, Australia.
Journal of Clinical Medicine
|September 28, 2023
Summary
Crohn's disease (CD) is a complex inflammatory bowel disease with varied presentations. Multi-omic approaches offer promising molecular markers for better understanding and personalized medicine in CD.
Area of Science:
- Gastroenterology
- Immunology
- Genetics
Background:
- Crohn's disease (CD) is a significant global health concern, affecting millions worldwide.
- CD is characterized by heterogeneous clinical presentations and complex pathophysiology.
- Current classification systems do not fully capture the heterogeneity of CD.
Purpose of the Study:
- To highlight the complexity and heterogeneity of Crohn's disease.
- To explore the potential of multi-omic approaches in identifying molecular markers for CD.
- To discuss the future implications for personalized medicine in CD management.
Main Methods:
- Review of existing literature on Crohn's disease pathophysiology and classification.
- Exploration of various omics technologies including genomics, transcriptomics, proteomics, epigenomics, metagenomics, metabolomics, lipidomics, and immunophenomics.
- Discussion of technological advancements in identifying small molecules for disease differentiation.
Main Results:
- The heterogeneity of CD is not adequately represented in current classification systems.
- Multi-omic data provides numerous targets for potential molecular markers.
- Advancing technologies enable the identification of small molecules for differentiating CD subtypes.
Conclusions:
- The multi-omic landscape of Crohn's disease holds significant promise for advancing disease pathogenesis understanding.
- Personalized medicine approaches for Crohn's disease are becoming increasingly feasible.
- Future research should focus on integrating multi-omic data for improved diagnostics and therapeutics.
Related Concept Videos
01:30Inflammatory Bowel Disease II: Crohn's Disease
279
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
279
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
164
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
164
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
01:17Chronic Bowel Disorders: Introduction
474
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
474
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
207
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
207